The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica Is BPC 157 Legal? Understanding Its Status and Implications The Hidden Risks of BPC157: What Patients Need to Know About Contamination and Safety Regenexx at New Regeneration Orthopedics FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC FDA Peptide Reclassification 2026: What It Means for Providers